Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

NEOGENOMICS, INC.

(NEO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

NEOGENOMICS INC : Change in Directors or Principal Officers (form 8-K)

11/10/2021 | 05:08pm EST
Item 5.02         Departure of Directors or Certain Officers; Election of Directors;
                  Appointment of Certain Officers; Compensatory Arrangements of Certain
                  Officers.


Board of Director Transitions On November 4, 2021, the Board of Directors (the "Board") of NeoGenomics, Inc., a Nevada corporation (the "Company"), voted to appoint David Daly to serve as a member of the Board, effective November 10, 2021. Mr. Daly will serve as a member of the Board until the 2022 annual meeting of shareholders of the Company or until his resignation or removal and otherwise until his successor is elected. Mr. Daly will receive compensation for his service as a director consistent with the Company's director compensation program previously disclosed in the Company's definitive proxy statement for its 2021 annual meeting of shareholders, including pro-rated equity compensation. Effective today, Douglas VanOort has resigned from the Board.

Leadership Team Transitions On November 4, 2021, the Company announced that William Bonello, the Company's current President, Informatics, was appointed Chief Financial Officer of the Company, effective January 1, 2022. In addition, on November 4, 2021, the Company announced that Kathryn McKenzie, the Company's current Chief Financial Officer, was appointed Chief Sustainability and Risk Officer of the Company, also effective January 1, 2022.

© Edgar Online, source Glimpses

All news about NEOGENOMICS, INC.
01/19NEOGENOMICS INC : Change in Directors or Principal Officers (form 8-K)
AQ
01/19Neogenomics, Inc. Announces Resignation of Kevin Johnson from Board of Directors
CI
01/12SVB Leerink Adjusts NeoGenomics Price Target to to $45 From $50, Maintains Outperform R..
MT
01/11NeoGenomics Unit Receives CE Mark for Its RaDaR Liquid Biopsy Assay
MT
01/11NEOGENOMICS : Announces RaDaR(TM) Assay Receives CE Mark and is Submitted for US Reimburse..
PU
2021Cowen Starts NeoGenomics at Outperform with $42 Price Target
MT
2021NeoGenomics Appoints David Eberhard Chief Medical Officer for Inivata
MT
2021NEOGENOMICS : Appoints David Eberhard MD, PhD as Chief Medical Officer of Inivata Liquid B..
PU
2021NEOGENOMICS : to Leverage Thermo Fisher Scientific's Ion Torrent Genexus System in Upcomin..
PU
2021Needham Adjusts NeoGenomics' Price Target to $41 From $48; Buy Rating Kept
MT
More news
Analyst Recommendations on NEOGENOMICS, INC.
More recommendations
Financials (USD)
Sales 2021 485 M - -
Net income 2021 0,68 M - -
Net Debt 2021 288 M - -
P/E ratio 2021 -12 928x
Yield 2021 -
Capitalization 2 658 M 2 658 M -
EV / Sales 2021 6,08x
EV / Sales 2022 5,32x
Nbr of Employees 1 700
Free-Float 95,7%
Chart NEOGENOMICS, INC.
Duration : Period :
NeoGenomics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NEOGENOMICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 12
Last Close Price 21,59 $
Average target price 47,64 $
Spread / Average Target 121%
EPS Revisions
Managers and Directors
Mark Mallon Chief Executive Officer & Director
George A. Cardoza President & Chief Operating Officer-Lab Operations
William Bishop Bonello Chief Financial Officer
Lynn A. Tetrault Non-Executive Chairman
Steven A. Ross Chief Information Officer & Vice President
Sector and Competitors